Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects

Author(s): Kelley DS, Adkins Y

Abstract

We have reviewed effects of long chain (LC) n-3 PUFA on markers of atherosclerosis in human subjects with a focus on individual effects of EPA and DHA. Initial results from epidemiological studies suggested that LC n-3 PUFA from fish oils (FO) reduced incidence of CVD; those results have been confirmed in interventional studies. Dietary intervention with n-3 PUFA decreased fasting and postprandial TAG, number of remnant-like chylomicron particles, large VLDL, and total and small dense LDL particles. It increased mean size of LDL particles by increasing number of large and decreasing those of small dense particles. With some exceptions, n-3 PUFA decreased blood pressure (BP) and heart rate (HR), flow-mediated dilation (FMD) and plasma concentrations of inflammatory markers. n-3 PUFA also decreased circulating adhesion molecules and intima-media thickness (IMT) in some but not other studies. For IMT, results varied with the sex and artery being examined. EPA effects on FMD are endothelial cell dependent, while those of DHA seem to be endothelial cell independent. Individually, both EPA and DHA decreased TAG and inflammatory markers, but only DHA decreased HR, BP and number of small dense LDL particles. Results varied because of dose and duration of n-3 PUFA, EPA:DHA, health status of subjects and other reasons. Future studies are needed to determine optimal doses of EPA and DHA individually, their synergistic, additive or antagonistic effects, and to understand underlying mechanisms. In conclusion, n-3 PUFA decreased several risk factors for atherosclerosis without any serious adverse effects.

Similar Articles

Heart disease and stroke statistics - 2014 update: a report from the American Heart Association

Author(s): Go AS, Dariush M, Véronique L, Emelia JB, Jarett DB, et al.

Nutritional assessment in heart failure patients

Author(s): Lee JH,Jarreau T, Prasad A, Lavie C, O'Keefe J, et al.

Aging and energetics' 'Top 40' future research opportunities 2010-2013

Author(s): Allison DB, Antoine LH, Ballinger SW, Bamman MM, Biga P, et al.

Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence

Author(s): Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, et al.

Omega-3 fatty acids: a growing ocean of choices

Author(s): Fares H,Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV

Omega-3s and cardiovascular health

Author(s): DiNicolantonio JJ,Niazi AK, McCarty MF, O'Keefe JH, Meier P, et al.

The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid

Author(s): Rodriguez-Leyva D,Dupasquier CM, McCullough R, Pierce GN

Comparative effects of DHA and EPA on cell function

Author(s): Gorjão R,Azevedo-Martins AK, Rodrigues HG, Abdulkader F, Arcisio-Miranda M, et al.

Pleiotropic effects of omega-3 fatty acids

Author(s): Papazafiropoulou AK,Kardara MS, Pappas SI

Omega-3 fatty acids and HDL

Author(s): Burillo E, Martín-Fuentes P, Mateo-Gallego R, Baila-Rueda L, Cenarro A, et al.

Omega-3 fatty acids and depression: scientific evidence and biological mechanisms

Author(s): Grosso G,Galvano F,Marventano S,Malaguarnera M,Bucolo C, et al.

Infusion of docosahexaenoic acid protects against myocardial infarction

Author(s): Richard D,Oszust F, Guillaume C,Millart H, Laurent-Maquin D, et al.